⚡ Quick Answer
What is the breast mesh lawsuit? Women are suing manufacturers of surgical mesh devices — including Becton Dickinson (BD), C.R. Bard, and MTF Biologics — alleging these products were used off-label in breast reconstruction, augmentation, and internal bra procedures without adequate testing, FDA approval, or patient warning. The FDA has explicitly stated that no surgical mesh is approved for breast surgery, and has flagged specific brands — including GalaFLEX, Phasix, AlloMax, and FlexHD — for elevated complication rates. Patients report infections, tissue necrosis, implant loss, chronic pain, and permanent disfigurement. Litigation is in early investigative stages with no MDL or settlements yet — but attorneys are actively accepting cases as filings grow.
Who Qualifies for a Breast Mesh Lawsuit
Eligibility focuses on women who received surgical mesh during breast surgery and suffered serious complications. Many patients do not know mesh was used until they review their operative reports — you may still qualify even if you were never told mesh was implanted or that it was being used off-label.
Qualifying Criteria:
How Breast Mesh Manufacturers Caused Harm
Lawsuits allege that mesh manufacturers sold surgical products for use in breast surgery without breast-specific FDA approval, adequate clinical testing, or honest patient warnings — all while knowing the products carried serious, documented risks in this setting. Four core patterns of alleged misconduct appear across active claims:
1. Selling Mesh for Off-Label Breast Use Without FDA Approval
The FDA has clearly stated that no surgical mesh product has been cleared or approved for breast augmentation or reconstruction. Despite this, manufacturers marketed and sold mesh products — originally developed for hernia repair and soft-tissue reinforcement — to plastic surgeons for use in breast procedures. Lawsuits allege manufacturers actively promoted this off-label use while concealing the undefined risk profile.
2. Failure to Warn Patients and Surgeons About Known Risks
Complaints allege manufacturers knew — or should have known — that their mesh products carried elevated risks of infection, tissue death, capsular contracture, mesh migration, and reconstruction failure when used in the breast environment. Patients and surgeons were not adequately warned, leaving women to undergo procedures without understanding the true risk of devastating complications.
3. Inadequate Testing for the Breast Environment
The breast is a fundamentally different environment from the abdominal wall where hernia mesh was originally tested. Lawsuits allege manufacturers failed to conduct breast-specific clinical studies before promoting these products to plastic surgeons. The unique conditions of the breast — including soft tissue dynamics, implant interactions, and proximity to skin — were not adequately studied, leaving patients exposed to unpredictable failure modes.
4. History of Ignoring Mesh Failure Signals
Many of the same manufacturers now facing breast mesh claims previously faced billions of dollars in vaginal mesh and hernia mesh lawsuits over nearly identical failure patterns — erosion, infection, tissue damage, and chronic pain. Complaints allege that despite this documented history of mesh-related harm in other body areas, manufacturers continued selling similar products for breast use without meaningful safety improvements or honest disclosure.
Breast Mesh Complications Recognized in Active Claims
The strongest cases involve serious, documented complications directly linked to breast mesh or internal bra devices. Both physical and emotional damages are recognized in these claims.
Settlement Outlook & Key Value Drivers
No settlements or verdicts have been reached in breast mesh litigation as of early 2026. Cases are in the early investigative stage. When settlements occur, compensation will depend on several key factors:
- 🔴
Severity of complications — infection requiring hospitalization, tissue necrosis, implant loss, or reconstruction failure typically yield the highest compensation
- 🔴
Number of revision or removal surgeries — each additional corrective procedure demonstrates the ongoing harm and increases medical damages
- 📋
Documentation strength — operative reports identifying the mesh product, imaging, pathology, infection records, and revision surgical notes are essential
- 📅
Long-term outcomes — permanent disfigurement, chronic pain, nerve damage, or inability to pursue further reconstruction significantly increase claim value
- 🔍
Specific mesh product — brands explicitly flagged by the FDA (FlexHD, AlloMax, GalaFLEX, Phasix) may present stronger liability arguments
- ⚖️
Prior mesh litigation framework — vaginal mesh lawsuits resulted in over $8 billion in settlements; hernia mesh MDLs involve 26,000+ pending cases; breast mesh litigation is expected to follow a similar trajectory
Disclaimer: No settlements have been reached. Projections are educational only and not a guarantee of outcome. Actual results depend on case-specific facts and litigation developments.
Deadlines for Filing a Breast Mesh Lawsuit (State-by-State)
Product liability statutes of limitations typically range from 2 to 3 years, but the clock often starts from the date you discovered — or reasonably should have discovered — that your complications were linked to the mesh, not the date of surgery. Many women don't connect their symptoms to mesh for months or years. Missing your deadline permanently bars your claim.
| State | Standard SOL | Discovery Rule | Notes |
|---|---|---|---|
| California | 2 years | Yes | Clock runs from discovery of injury link; active state for product liability filings |
| New York | 3 years | Yes | Longer standard window; discovery rule applies to latent medical device injuries |
| Texas | 2 years | Yes | 15-year statute of repose limits how far back claims can reach regardless of discovery |
| Florida | 2 years | Yes | SOL recently shortened from 4 years; consult an attorney immediately if surgery occurred several years ago |
| Illinois | 2 years | Yes | 8-year statute of repose from date of product sale; active venue for medical device litigation |
| New Jersey | 2 years | Yes | Home state of several mesh manufacturers; significant prior vaginal mesh litigation venue |
| All Other States | Typically 2–3 years | Usually yes | Discovery rules and statutes of repose vary. Do not assume it is too late — consult an attorney immediately to confirm your specific deadline. |
Because many breast mesh complications develop gradually and are not immediately linked to the implanted mesh, discovery rules may significantly extend your filing window. Do not assume it is too late without speaking to an attorney.
Breast Mesh Lawsuit Updates — 2026
Last updated June 2026. We update this section as new filings, regulatory actions, and litigation developments occur.
-
Early 2026 LatestAttorneys Actively Accepting Cases; No MDL or Settlement Yet: As of early 2026, breast mesh litigation is in the investigative and early filing stage. There is no MDL or class action yet, and no settlements or jury verdicts have been reached. Attorneys nationwide are accepting cases and gathering evidence as the number of claims grows. Observers note that this litigation is following a trajectory similar to vaginal mesh and hernia mesh lawsuits — both of which began as individual investigations before consolidating into major MDLs and ultimately resulting in billions of dollars in settlements.
-
October 31, 2025Investigations Into Internal Bra Mesh Manufacturers Reported: Reports emerge that manufacturers of internal bra mesh used in breast augmentation are facing investigations with the potential to lead to formal litigation. Legal observers note these mesh products present similar risks to those underlying the ongoing hernia mesh litigation, calling this potentially "the next big wave of mesh-related lawsuits in the United States."
-
2023FDA Requires Becton Dickinson to Update Breast Mesh Labeling: The FDA issues a letter requiring Becton Dickinson to update labeling on its GalaFLEX and Phasix mesh products used in soft-tissue reinforcement. The letter explicitly warns health care providers that these products are not cleared or approved for breast augmentation or reconstruction, and that the benefit-risk profile of mesh in the breast setting remains undefined. BD is required to update warnings and precautions to reflect these uncertainties.
-
2021FDA Warns About Elevated Complication Rates in Breast Mesh Products: The FDA issues a safety communication warning about differing complication rates among acellular dermal matrix (ADM) products used in implant-based breast reconstruction. The agency specifically flags FlexHD (MTF Biologics) and AlloMax (C.R. Bard/BD) for higher rates of major complications, explantation, reoperation, and infection compared with other ADMs or no ADM at all — a landmark regulatory signal that these products carry unequal and elevated risk.
-
BackgroundSame Manufacturers, Same Pattern — Vaginal & Hernia Mesh Precedent: Becton Dickinson (via C.R. Bard acquisition), Ethicon (J&J), and Boston Scientific collectively paid over $8 billion to resolve more than 107,000 vaginal mesh lawsuits — many involving nearly identical failure patterns (erosion, infection, chronic pain, tissue damage). Those same companies then sold similar mesh products for use in breast surgery without breast-specific FDA approval. Hernia mesh litigation involving Bard and Covidien currently has over 26,000 pending cases. Legal experts view breast mesh as the next major wave of mesh-related mass tort litigation.
Find Out If You Qualify — Free Case Review
Attorneys are reviewing breast mesh and internal bra cases nationwide. You pay nothing unless compensation is recovered.
Start My Free Case ReviewHow the Breast Mesh Lawsuit Process Works
Attorneys accept breast mesh cases on contingency — you pay nothing unless compensation is recovered.
- Free confidential consultation — Discuss your surgical history, complications, and timeline with an attorney at no cost. No records are required before reaching out.
- Obtaining your operative records — The most critical step is identifying the specific mesh product used. Your attorney can help obtain operative reports, surgical notes, and product records from the hospital or surgeon's office.
- Case review and medical assessment — Your attorney reviews all records alongside medical experts to establish a connection between the mesh product and your complications. This includes imaging, pathology, infection records, and revision surgical notes.
- Identifying the defendants — Claims are filed against the mesh manufacturer(s) responsible for the specific product used in your procedure. Multiple manufacturers may be named depending on what your records reveal.
- Filing the lawsuit — Your attorney files suit in the appropriate state or federal court. As the number of cases grows, consolidation into an MDL is possible — your attorney will monitor developments and position your case accordingly.
- Discovery — Both sides exchange evidence: manufacturer internal documents, clinical testing records, communications about known complication risks, FDA correspondence, and marketing materials provided to surgeons.
- Expert testimony — Plastic surgeons, biomedical engineers, pathologists, and product safety experts testify about how the mesh failed and the adequacy of manufacturer warnings and testing.
- Settlement or trial — Cases may resolve through negotiated settlement or proceed to trial. Given the precedent from vaginal and hernia mesh litigation, early filers are often best positioned when global settlement discussions begin.
Frequently Asked Questions
What is the breast mesh lawsuit about?
Breast mesh lawsuits claim that surgical mesh devices — originally cleared for hernia and soft-tissue repair — were sold and marketed for off-label use in breast reconstruction, augmentation, and internal bra procedures without breast-specific FDA approval or adequate safety testing.
Women who suffered serious complications including infection, tissue necrosis, chronic pain, implant loss, and permanent disfigurement are filing claims against manufacturers including Becton Dickinson, C.R. Bard, and MTF Biologics for failing to warn about these risks.
Who qualifies for a breast mesh or internal bra lawsuit?
You may qualify if you received surgical mesh during breast reconstruction, augmentation, lift, or revision surgery and subsequently developed serious complications — including infection, abscess, tissue necrosis, chronic pain, mesh erosion, capsular contracture, or implant loss — that required additional medical intervention or revision surgery.
Many patients qualify without knowing mesh was used until reviewing their operative reports. An attorney can help you obtain those records.
Which mesh products are named in breast mesh lawsuits?
Products under investigation include GalaFLEX and Phasix (Becton Dickinson/BD), AlloMax (C.R. Bard/BD), FlexHD (MTF Biologics), AlloDerm (Allergan/LifeCell), SurgiMend (Integra LifeSciences), and other synthetic and biologic mesh used off-label in breast procedures. The FDA has specifically flagged BD products and cited higher complication rates with FlexHD and AlloMax in breast reconstruction patients.
Was breast mesh approved by the FDA?
No. The FDA has explicitly stated that no surgical mesh product has been cleared or approved for breast augmentation or reconstruction. Despite this, these products were widely used off-label in breast procedures.
In 2023, the FDA required Becton Dickinson to update labeling on GalaFLEX and Phasix to warn that these products are not approved for breast surgery. In 2021, the FDA issued a safety communication flagging elevated complication rates with specific ADM products used in breast reconstruction.
What evidence do I need for a breast mesh lawsuit?
Your operative report is the most critical document — it identifies the specific mesh product used during surgery. Other important evidence includes pathology reports, imaging (ultrasound, MRI, CT), hospital records related to infection or emergency treatment, records of revision or removal surgeries, photos documenting complications, and billing records.
You do not need all records in hand before reaching out. Your attorney can help identify what is needed and assist in obtaining records from your surgeon or hospital.
Is there a breast mesh class action or MDL?
As of early 2026, there is no finalized breast mesh MDL or class action. Litigation is in the early investigative and filing stage. As the number of cases grows, MDL consolidation is expected — mirroring the path of vaginal mesh litigation (7 separate MDLs, 107,000+ cases, $8B+ in settlements) and hernia mesh litigation (26,000+ pending cases across multiple MDLs).
How long do I have to file a breast mesh lawsuit?
Statutes of limitations typically range from 2 to 3 years, but in most states the clock starts when you discovered — or reasonably should have discovered — that your complications were linked to the mesh, not the date of surgery. Many women don't connect their symptoms to mesh until years after the procedure.
Do not assume it is too late without consulting an attorney. Filing sooner is always advisable, as evidence and records are easier to obtain and your case will be better positioned when settlement discussions begin.
